Condition | Cancer

NRG BR003

  • IRB Number: NRG-BR003
  • Contact Name: Rachel O’Loughlin, RN BSN
  • Status: Enrolling
  • Phone: (585) 747-4555
  • Lead Researcher: Peter Bushunow, MD

Description

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

https://clinicaltrials.gov/ct2/show/NCT02488967?term=NRG+BR003&rank=1